Shots:

• The P-III IMpassion031 study involves assessing of Tecentriq + CT (Abraxane- nab-paclitaxel; followed by doxorubicin and cyclophosphamide) vs PBO + CT in 333 people in a ratio (1:1) with previously untreated- early TNBC- regardless of PD-L1 expression
• Results: met its 1EPs by demonstrating a clinically meaningful improvement in pathological complete response. Patients who received the Tecentriq combination as a neoadjuvant treatment had evidence of tumor tissue detectable at the time of surgery- regardless of PD-L1 expression
• Tecentriq + nab-paclitaxel is currently approved in 70+ countries worldwide- including the US and across EU- for the treatment of adults with unresectable LA/metastatic TNBC in people whose tumors express PD-L1

Click here to read full press release/ article 

Ref: Roche | Image: Roche